Cantor Fitzgerald set a $10.00 target price on Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a research note published on Tuesday morning. The brokerage currently has a hold rating on the stock.

A number of other research analysts also recently issued reports on TEVA. Oppenheimer Holdings, Inc. restated a hold rating on shares of Teva Pharmaceutical Industries Limited in a research report on Sunday, November 12th. J P Morgan Chase & Co downgraded shares of Teva Pharmaceutical Industries Limited from a neutral rating to an underweight rating and cut their target price for the company from $11.48 to $11.00 in a research report on Monday. downgraded shares of Teva Pharmaceutical Industries Limited from a hold rating to a reduce rating in a research report on Tuesday, November 7th. Susquehanna Bancshares Inc cut their target price on shares of Teva Pharmaceutical Industries Limited from $20.00 to $14.00 and set a positive rating on the stock in a research report on Monday, November 6th. Finally, Credit Suisse Group restated an underperform rating and set a $8.00 target price (down from $14.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, November 6th. Seven equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $21.88.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded up $1.05 during trading hours on Tuesday, reaching $13.84. 40,789,469 shares of the company’s stock were exchanged, compared to its average volume of 15,421,583. Teva Pharmaceutical Industries Limited has a 12-month low of $10.85 and a 12-month high of $39.08. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. The company has a market cap of $12,270.00, a price-to-earnings ratio of 2.71 and a beta of 0.52.

COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Analysts Give Teva Pharmaceutical Industries Limited (TEVA) a $10.00 Price Target” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/11/17/cantor-fitzgerald-analysts-give-teva-pharmaceutical-industries-limited-teva-a-10-00-price-target.html.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a dividend of $0.085 per share. The ex-dividend date is Monday, November 27th. This represents a $0.34 annualized dividend and a dividend yield of 2.46%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently -16.01%.

Institutional investors and hedge funds have recently modified their holdings of the company. San Francisco Sentry Investment Group CA bought a new position in shares of Teva Pharmaceutical Industries Limited during the 2nd quarter worth approximately $106,000. Kistler Tiffany Companies LLC grew its stake in shares of Teva Pharmaceutical Industries Limited by 74.7% during the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after acquiring an additional 1,571 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after acquiring an additional 94 shares in the last quarter. Cutler Capital Management LLC bought a new position in shares of Teva Pharmaceutical Industries Limited during the 2nd quarter worth approximately $133,000. Finally, Shelter Mutual Insurance Co bought a new position in shares of Teva Pharmaceutical Industries Limited during the 2nd quarter worth approximately $133,000. 55.81% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.